Objective. Allogeneic mesenchymal stem cells (MSCs) exhibit therapeutic effects in human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms remain largely unknown. The aim of this study was to investigate how allogeneic MSCs mediate immunosuppression in lupus patients.
anisms by which allogeneic MSC transplantation ameliorates SLE remain largely unknown.
It is now clear that MSCs exert immunoregulatory properties on various immune cells. This includes suppression of T cell proliferation, regulation of dendritic cell (DC) maturation and function, modulation of B cell proliferation and terminal differentiation, and regulation of natural killer cells and macrophage function (10) (11) (12) . Many factors are involved in MSC immunomodulation, including but not limited to, production of transforming growth factor ␤ (TGF␤), hepatocyte growth factor (HGF), prostaglandin E 2 (PGE 2 ), interleukin-10 (IL-10), indolamine 2,3-dioxygenase (IDO), nitric oxide (NO), heme oxygenase 1 (HO-1), and HLA-G (13) (14) (15) (16) . IDO, which is mainly produced by DCs and macrophages, is an enzyme that degrades the essential amino acid tryptophan and participates in immune tolerance (17, 18) . In 2004, a study demonstrated that human MSCs could secrete IDO in vitro in the presence of mixed lymphocyte reaction. The IDO that was secreted by MSCs mediated inhibition of normal T cell proliferation (19) . However, other studies have demonstrated that IDO plays a dispensable role in human MSC suppression of T cell proliferation and have instead suggested that HLA-G and IL-10 have a cellcontact-dependent role (20) . In animal studies, it has been suggested that NO rather than IDO is involved in immunomodulation by MSCs (21) . Importantly, the precise mechanisms responsible for the regulatory effects of MSCs in lupus patients remain unknown.
In this study, we determined that high levels of interferon-␥ (IFN␥), produced predominantly by CD8ϩ T cells in lupus patients, are a key factor involved in the stimulation of allogeneic UC-MSCs to produce IDO, which can then inhibit the proliferation of T cells from lupus patients. Thus, we uncovered a previously unrecognized CD8ϩ T cell/IFN␥/IDO axis that mediates the therapeutic benefit of allogeneic MSCs in lupus.
PATIENTS AND METHODS
Lupus patients and healthy subjects. Seventy-nine SLE patients and 89 healthy subjects were included in this study. Informed consent was obtained from each subject for the collection of peripheral blood or BM. Clinical study of UC-MSC transplantation among lupus patients was registered with ClinicalTrials.gov (identifier: NCT01741857). Six patients underwent UC-MSC transplantation as previously described (3) . This study was approved by the Ethics Committee at The Affiliated Drum Tower Hospital of Nanjing University Medical School and was conducted in accordance with the 1989 Declaration of Helsinki.
Antibodies and reagents.
The following antibodies (to humans) were used in this study: fluorescein isothiocyanate (FITC)-conjugated anti-human CD3 (OKT3), anti-CD4 (11830), anti-HLA-DR (L203), phycoerythrin (PE)-conjugated anti-human CD4 (11830), allophycocyanin (APC)-conjugated anti-human CD8 (RPA-T8), CD25 (M-A251), and the respective isotype-matched control antibodies (mouse IgG1 and mouse IgG2a) (all from BD Biosciences); and FITC-conjugated anti-human CD34 (4H11), CD44 (IM7), PE-conjugated anti-human CD45 (HI30), CD29 (TS2/16), CD166 (3A6), CD138 (DL-101), FoxP3 (150D/14), PE-Cy7-conjugated FoxP3 (PCH101), APC-conjugated anti-human CD4 (RPA-T4), CD19 (HIB19), PE-Cy7-conjugated antihuman IFN␥ (4S.B3), purified anti-human CD3 (OKT3), CD28 (CD28.2), CD40 (5C3) (no azide and low endotoxin) (all from eBioscience). Recombinant human TGF␤1 and antihuman TGF␤ antibody were both from R&D Systems. Recombinant human IL-2, IL-4, IL-10, IL-6, tumor necrosis factor ␣, IFN␥, IL-1␤, IFN␣, and IFN␤ were from PeproTech. 1-methyl-DL-tryptophan was from Sigma-Aldrich. F(abЈ) 2 fragment goat anti-human IgM was from Jackson ImmunoResearch. Purified anti-human IFN␥ (NIB42) and mouse IgG1 isotype (no azide and low endotoxin) were from BioLegend. Human HGF, total IgG, and IgM enzyme-linked immunosorbent assay (ELISA) kits were from eBioscience. The human TGF␤1 ELISA kit was from BioLegend. Cell isolation kits were from Miltenyi Biotec.
Human MSC isolation and purification. Human MSCs were isolated from the UC and BM of lupus patients and healthy subjects. Information on the purification and identification of MSCs is available upon request from the corresponding author.
Isolation and culture of T cells. Peripheral blood mononuclear cells (PBMCs) were isolated from patients with active lupus and healthy controls. CD4ϩ and CD8ϩ T cell subsets were purified by positive isolation using microbeads (Miltenyi Biotec). CD4ϩCD25Ϫ and CD4ϩCD25ϩ T cell subsets were purified using a human CD4ϩCD25ϩ regulatory T cell isolation kit (Miltenyi Biotec). CD4ϩ T cells were purified using negative isolation, then CD25 T cells were purified using positive isolation. The purified CD4ϩ or CD8ϩ T cell subsets were cocultured with or without pre-plated allogeneic human MSCs (4:1) in the presence of soluble anti-human CD3 (2 g/ml) and anti-human CD28 (2 g/ml) antibodies, and a non-CD4/CD8 T cell subset was used as a control. After 48 hours, nonadherent cells were removed and supernatants were collected for measurement of cytokines (IFN␥ and TGF␤1) by ELISA (BioLegend). The adherent MSCs were washed 3 times with phosphate buffered saline (PBS) and lysed with TRIzol (Takara) for real-time polymerase chain reaction (PCR) analysis. In some experiments, a Transwell system (0.4 m pore size; Millipore) was used to block cell-cell contact.
Treg cell differentiation in vitro. CD4ϩCD25Ϫ T cells were cultured with soluble anti-CD3 (2 g/ml) and anti-CD28 (2 g/ml) antibodies, with the addition of recombinant human TGF␤1 (10 ng/ml) and IL-2 (100 IU/ml) to induce Treg cell conversion (22, 23) . In some cultures, allogeneic human MSCs or human lung fibroblast (HLF) cells were initially included. Cells were cultured for 5 or 6 days and collected for measurement of Treg cells.
T cell proliferation assay. For the carboxyfluorescein succinimidyl ester (CFSE)-labeling assay, 10 6 cells/ml of PBMCs or purified T cells were incubated with 3 moles/liter of CFSE in PBS/0.5% bovine serum albumin (BSA) at 37°C for 15 minutes. Cells were washed 3 times with fresh, ice-cold complete 1640 medium and resuspended in complete 1640 medium for further culture. After the cells were cultured for several days as indicated, cells were harvested to examine the CFSE-negative cells using flow cytometry.
Flow cytometric analysis. PBMCs or purified T cells were resuspended in PBS containing 1% BSA and 0.1% sodium azide. For the staining of surface antigens, cells were incubated with FITC-conjugated, PE-conjugated, or APCconjugated monoclonal antibodies or their negative control antibodies for 30 minutes on ice as indicated. Intracellular staining of FoxP3 and IFN␥ was performed as described previously (3, 24) .
Real-time quantitative PCR. Complementary DNA (cDNA) was synthesized from TRIzol-isolated total RNA using a SuperScript III First Strand Synthesis SuperMix for quantitative reverse transcription-PCR (Takara). For realtime PCR experiments, reactions containing SYBR Premix EX Taq (Takara), ROX Reference Dye (50ϫ; Takara), cDNA, and gene primers were run on a StepOnePlus real-time PCR system and analyzed using StepOne Software, version 2.1 (Applied Biosystems). Gene primers are available upon request from the corresponding author. Relative gene quantification was calculated by the 2
Ϫ⌬⌬Ct method and then normalized to the level of GAPDH (25) .
Western blot analysis and ELISA. We used antibodies recognizing human STAT-1, STAT-3, STAT-5, Akt, IB, ERK and their phosphorylation forms, p52, p65, and GAPDH (1:1,000; Cell Signaling Technology) to examine the concentrations of proteins in MSCs lysates. The concentration of IDO protein in MSCs (1:400 dilution; Epitomics Technology) was also determined (methods are available upon request from the corresponding author).
We detected amounts of HGF, TGF␤1, and IFN␥ in the conditioned media and/or human serum using ELISA kits (eBioscience or BioLegend) according to the manufacturer's instructions.
High-performance liquid chromatography. Kynurenine and tryptophan concentrations were analyzed by highperformance liquid chromatography as reported (26) (methods are available upon request from the corresponding author).
Statistical analysis. We used a t-test for statistical analysis of parametric data and the Mann-Whitney test for analysis of nonparametric data. One-way analysis of variance was used when there were Ͼ2 groups, followed by the Bonferroni test. Statistical analyses were performed with SPSS version 16.0 and GraphPad Prism version 4.3 software packages. Data are presented as the mean Ϯ SEM. P values less than 0.05 were considered significant.
RESULTS
Allogeneic UC-MSC inhibition of the proliferation of T cells from lupus patients. MSCs have been reported to inhibit T cell proliferation in healthy subjects (27, 28) , but whether this can occur in patients with lupus remains largely unknown. We first investigated whether allogeneic UC-MSCs regulated T cell proliferative responses in lupus patients. We found that UC-MSCs significantly inhibited the proliferation of anti-CD3 and anti-CD28-activated CD4ϩ T lymphocytes from both healthy controls and lupus patients ( Figure 1A ). The allogeneic normal human fibroblasts (HLF cells) that served as controls, however, exhibited no suppression of T cell proliferation ( Figure 1A ). To determine which subset of CD4ϩT cells was inhibited by UC-MSCs, we separated CD4ϩCD25Ϫ (responder) and CD4ϩCD25ϩ (predominantly regulatory) T cells from the peripheral CD4ϩ T cells of patients and found that UC-MSCs efficiently inhibited CD4ϩCD25Ϫ T cell proliferation ( Figure 1B ), while they promoted CD4ϩCD25ϩ Treg cell proliferation and maintained their survival in vitro ( Figures 1C and D) .
To study whether UC-MSC-mediated suppression was due to conversion of induced CD4ϩCD25ϩ Treg cells (23), we stimulated CD4ϩCD25Ϫ T cells with anti-CD3/CD28 (2 g/ml), TGF␤ (10 ng/ml), and IL-2 (100 IU/ml) in the presence and absence of UC-MSCs or HLF cells. As expected, fewer induced Treg cells were differentiated in lupus CD4ϩCD25Ϫ T cells as compared to healthy control T cells ( Figure 1E ). Surprisingly, UC-MSCs failed to enhance and actually inhibited the conversion to induced Treg cells both in healthy controls and in lupus patients ( Figure 1E ), whereas HLF cells had no effect. Thus, UC-MSCs blocked T cell receptor (TCR)-driven lupus CD4ϩ T cell proliferation, which was not attributable to induced Treg cell conversion.
Role of IDO in UC-MSC-mediated inhibition of lupus T cell proliferation. We next investigated the underlying molecular mechanisms by which UC-MSCs suppressed lupus T cell proliferation. We hypothesized that UC-MSCs expressed or secreted molecules/factors in lupus patients that in turn inhibited T cell proliferation. To assess this, we cultured UC-MSCs with PBMCs isolated from patients with active SLE or healthy controls, in the absence or presence of soluble anti-CD3 and anti-CD28 antibodies (both 1 g/ml). After 48 hours, PBMCs were removed through extensive washing, and the molecules and cytokines produced by UC-MSCs were determined. We examined HGF, TGF␤1, and IDO, since they have all been reported to influence MSC-mediated T cell proliferation (19, 28) . Although unstimulated lupus PBMCs increased HGF and TGF␤1 mRNA levels and protein levels in UC-MSCs as compared to untreated or normal PBMC-treated UC-MSCs, TCR-stimulated lupus PBMCs failed to further up-regulate the aforementioned cytokines (Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.38674/abstract). Strikingly, however, TCRstimulated lupus PBMCs drove UC-MSCs to produce extremely high levels of mRNA for IDO (Ͼ200-fold) ( Figure 2A ). We also saw enhanced IDO enzyme activity ( Figure 2B ) and larger amounts of protein ( Figure  2C ) as compared to untreated or healthy PBMC-treated UC-MSCs.
The increase in IDO levels by UC-MSCs in response to lupus PBMCs prompted us to determine whether IDO was involved in UC-MSC-mediated suppression of lupus T cell proliferation. For this, we added 1-methyl-DL-tryptophan the inhibitor of IDO enzyme activity, to the cocultures of UC-MSCs and TCRstimulated lupus PBMCs that had been prelabeled with CFSE. While the IDO inhibitor itself had no effect on TCR-driven T cell proliferation, it completely reversed the suppression of lupus T cell proliferation mediated by UC-MSCs ( Figure 2D ).
We next determined whether IDO-mediated inhibition of cell proliferation by UC-MSCs was specific to T cells. We examined effects of IDO on UC-MSCmediated B cell suppression. PBMCs from lupus patients were cocultured with allogeneic UC-MSCs, and B cells were stimulated with anti-human CD40 and antihuman IgM (F[abЈ] 2 ). We found that UC-MSCs inhibited B cell differentiation (as determined by CD138 staining), proliferation (as determined by CFSE labeling), and IgG production (as determined by ELISA) (Supplementary Figure 2 we found that IDO plays a key role in MSC-mediated suppression of T cells from lupus patients, although the same is not true for B cells. We also wanted to determine whether the enhanced proliferation of Treg cells by UC-MSCs was dependent upon IDO. UC-MSCs were cocultured in vitro with Treg cells from healthy controls or patients with active lupus. We found that healthy Treg cells failed to induce IDO in UC-MSCs, but lupus Treg cells induced some IDO gene expression in UC-MSCs (Supplementary Figure 2F ). In a coculture of lupus PBMCs and UC-MSCs, the addition of the TGF␤ kinase inhibitor SB431542 inhibited the proliferation of CD4ϩFoxP3ϩ Treg cells. Interestingly, the IDO inhibitor, 1-methyl-DL-tryptophan, had no effect on Treg cell proliferation (Supplementary Figure 2G) ; thus, the effect of MSCs on Treg cells is not IDO dependent.
Lupus CD8؉ T cell-derived IFN␥ promotion of IDO activity in UC-MSCs. To investigate which cell subset(s) in lupus PBMCs stimulates UC-MSC production of IDO, we first purified CD4ϩ T cells from the PBMCs of healthy controls and lupus patients. CD4ϩ T cells were cocultured with UC-MSCs for 48 hours in the presence of anti-CD3 and anti-CD28 antibodies. Non-CD4ϩ cells were used as controls. Unexpectedly, we found that non-CD4ϩ cells from lupus patients drove UC-MSCs to increase expression of mRNA for IDO and exhibited higher levels of IDO enzymatic activity when compared to CD4ϩ T cells from lupus patients (Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.38674/abstract).
To identify which cell type(s) in non-CD4ϩ cells was responsible for the IDO production of UC-MSCs, we separated CD4ϩ and CD8ϩ T cells and the non-CD4/CD8 cell population (B cells, monocytes, and other cells) from both lupus and healthy PBMCs and repeated the experiment. We determined that CD8ϩ T cells from lupus patients induced the highest levels of mRNA for IDO and its enzymatic activity ( Figures 3A and B) . Lupus CD4ϩ T cells also induced increased IDO levels in UC-MSCs, although the levels were significantly lower than those induced by CD8ϩ T cells ( Figures 3A  and B) . In healthy subjects, CD8ϩ T cells were also the most potent cells at stimulating IDO in UC-MSCs, but the levels of mRNA for IDO, as well as its activity, were significantly lower than that in lupus CD8ϩ T celltreated UC-MSCs ( Figures 3A and B) . Interestingly, neither lupus nor healthy non-CD4/CD8 cells from PMBCs induced a significant up-regulation of IDO in UC-MSCs ( Figures 3A and B) . To determine whether the ability of CD8ϩ T cells to increase IDO mRNA levels in UC-MSCs was dependent upon cell-cell contact, we separated CD8ϩ T cells from UC-MSCs in a Transwell coculture system. In cell-cell contact cultures, even when separated from the UC-MSCs, lupus CD8ϩ T cells induced levels of IDO similar to those induced in UC-MSCs ( Figure 3C ). These data suggest that a soluble factor(s) secreted from lupus CD8ϩ T cells stimulates IDO activity in UC-MSCs.
Since it has been reported that IFN␥ and TGF␤ are important factors for the initiation of IDO activity in DCs and macrophages (18) , we focused on these 2 cytokines in UC-MSCs. We found a significant increase in levels of IFN␥ in the supernatants of cultures containing UC-MSCs and TCR-stimulated lupus CD8ϩ T cells as compared to cultures containing CD4ϩ T cells or non-CD4/CD8 cells ( Figure 4A ), while levels of TGF␤1 were unchanged ( Figure 4B ). This IFN␥ was not produced by UC-MSCs, as the supernatants from CD8ϩ T cells alone contained similar amounts of IFN␥ ( Figure  4A ). To further confirm that IFN␥ was from CD8ϩ T cells, we examined intracellular IFN␥ expression in CD4ϩ, CD8ϩ, and non-CD4/CD8 cells using flow cytometry. We found that lupus CD8ϩ T cells produced the largest amounts of intracellular IFN␥ ( Figure 4C) . Importantly, the addition of anti-IFN␥ antibody to the cocultures of UC-MSCs and lupus CD8ϩ T cells completely abrogated IDO gene expression ( Figure 4D ) as well as supernatant kynurenine levels ( Figure 4E ). Moreover, anti-IFN␥ antibody completely restored TCR-driven lupus T cell proliferation that was inhibited by UC-MSCs; when anti-IFN␥ was added to cocultures, IDO enzyme activity was no longer increased ( Figures  4F-H) . The effect was comparable to that found when 1-DL-MT was added to the cocultures (Figures 4F-H) . In ‫ءءء‬ ϭ P Ͻ 0.001 by one-way ANOVA followed by Bonferroni test. NS ϭ not significant (see Figure 1 for other definitions).
contrast, neutralization of TGF␤ with anti-TGF␤ antibody failed to significantly decrease IDO activity and/or restore T cell proliferation in the same UC-MSCs and lupus PBMC cocultures ( Figure 4F-I ). These data collectively indicate that the IFN␥ that is secreted by lupus CD8ϩ T cells stimulates IDO activity in UC-MSCs and that enhanced levels of IDO then cause inhibition of T cell proliferation. Association of JAK/STAT pathways with enhanced levels of IDO activity in UC-MSCs. We next sought to elucidate the signaling pathways by which lupus CD8ϩ T cells induced IDO production in UCMSCs. In DCs, the initiation of IDO activity is mostly dependent upon noncanonical NF-B signaling pathways (29) . On the other hand, JAK/STAT signaling activation is involved in IFN␥-induced immune responses (30) . How CD8ϩ T cells induce IDO in UCMSCs is unknown. In vitro stimulation by lupus CD8ϩ T cells resulted in a significant increase in IFNGR1 but not IFNGR2 in UC-MSCs ( Figure 5A significantly up-regulated in the presence of lupus CD8ϩ T cells, an up-regulation which was similar to that seen when cells were stimulated with 20 ng/ml of recombinant human IFN␥ ( Figure 5B and Supplementary Figure 4B ). Furthermore, STAT-1 gene expression was also increased in these settings ( Figure 5C ). Western blot analysis confirmed the activation of STAT-1, STAT-3, and STAT-5 signaling pathways following coculture of lupus CD8ϩ T cells with UC-MSCs ( Figure  5D ). We also examined NF-B, ERK, and Akt pathways in UC-MSCs, but found no obvious activation in the presence of lupus CD8ϩ T cells (Supplementary Figure   4C) . Thus, IFNGR1/JAK-2/STAT signaling pathways are associated with the IDO activity in UC-MSCs that is stimulated by lupus CD8ϩ T cells. Defective IDO activity in lupus BM-MSCs. The profound IDO production by allogeneic UC-MSCs in response to lupus CD8ϩ T cells prompted us to explore whether MSCs in patients with active lupus had defective IDO activity. We therefore isolated MSCs from the BM of patients with active lupus and healthy subjects and cultured the cells in vitro. The expanded BM-MSCs were stimulated with IFN␥, and UC-MSCs were used as controls. We found that lupus BM-MSCs had signifi- . E, IDO mRNA expression in UC-MSCs, BM-MSCs from healthy controls, and BM-MSCs from SLE patients was examined after stimulation with different cytokines for 48 hours. F and G, Peripheral blood CD8ϩ T cells derived from patients with lupus were purified and used to stimulate UC-MSCs and BM-MSCs from healthy controls or lupus patients. Forty-eight hours later, IDO gene expression (F) and kynurenine enzyme activity (G) were determined. H, The ability of BM-MSCs from healthy controls and lupus patients to inhibit CD4ϩ T cell proliferation was compared. Bars in A-C and E-H show the mean Ϯ SEM (n ϭ 7 per group in A-D, 6 per group in E, 3 per group in F and G, and 4 per group in H). ‫ءء‬ ϭ P Ͻ 0.01; ‫ءءء‬ ϭ P Ͻ 0.001, by one-way ANOVA. TGF␤ ϭ transforming growth factor ␤; IL-6 ϭ interleukin-6; PBMC ϭ peripheral blood mononuclear cell; NS ϭ not significant (see Figure 1 for other definitions).
cantly lower IDO mRNA levels compared to healthy BM-MSCs or UC-MSCs, in response to IFN␥ stimulation ( Figure 5E ). When cocultured with allogeneic TCRactivated lupus CD8ϩ T cells, lupus BM-MSCs also exhibited a profound defect in IDO secretion and activity compared to normal BM-MSCs ( Figures 5F and G) . Importantly, when cocultured with allogeneic lupus PBMCs, lupus BM-MSCs had a reduced ability to suppress T cell proliferation as compared to normal BM-MSCs ( Figure 5H ). These data demonstrate a decrease in IDO levels in MSCs derived from lupus patients in response to IFN␥ and CD8ϩ T cells. Increased circulating IDO activity after UC-MSC transplantation in lupus patients. Since IFN␥ and CD8ϩ T cells trigger allogeneic MSCs to produce IDO and inhibit lupus T cell proliferation, we assessed whether IFN␥ and CD8ϩ T cells were increased in lupus patients. We therefore analyzed a clinical index in lupus patients in vivo. First, we compared circulating levels of IFN␥, CD4ϩ, and CD8ϩ T cell subsets in the peripheral blood of lupus patients and healthy controls. We found that lupus patients had a significantly higher frequency and total number of peripheral CD8ϩ T cells and increased levels of circulating IFN␥ (Figures 6A-C) . Moreover, there was an increased frequency and absolute number of IFN␥ϩCD8ϩ T cells from lupus patients compared to those from healthy controls ( Figures 6D  and E) . These data suggest that the lupus microenvironment can initiate the function of allogeneic MSCs in vivo. Importantly, we observed that serum IDO activity (as evidenced by kynurenine concentrations) was significantly increased in 6 lupus patients 1 month after intravenous UC-MSC transplantation ( Figure 6F ). Serum tryptophan levels, however, did not change ( Figure  6G ), while the ratio of kynurenine to tryptophan was markedly increased ( Figure 6H ). Furthermore, in another clinical study, we found that percentages of peripheral blood CD3ϩCD4ϩ T cells decreased after UC-MSC transplantation in patients (Supplementary Figure  5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.38674/ abstract). These data are consistent with our in vitro data and suggest that IDO plays a pivotal role in allogeneic MSC treatment in lupus patients.
DISCUSSION
The molecules that mediate MSC inhibition of lupus inflammatory cells remain incompletely understood. Herein we show that UC-MSC-produced IDO was critical for the inhibition of T cells and that IFN␥ produced by lupus CD8ϩ T cells was the main factor 
